vs
Side-by-side financial comparison of Arcellx, Inc. (ACLX) and TECOGEN INC. (TGEN). Click either name above to swap in a different company.
Arcellx, Inc. is the larger business by last-quarter revenue ($8.1M vs $5.3M, roughly 1.5× TECOGEN INC.). TECOGEN INC. runs the higher net margin — -75.1% vs -766.0%, a 690.9% gap on every dollar of revenue. On growth, TECOGEN INC. posted the faster year-over-year revenue change (-12.5% vs -79.3%). TECOGEN INC. produced more free cash flow last quarter ($-2.6M vs $-63.9M). Over the past eight quarters, TECOGEN INC.'s revenue compounded faster (-7.3% CAGR vs -24.6%).
Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.
ACLX vs TGEN — Head-to-Head
Income Statement — Q1 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.1M | $5.3M |
| Net Profit | $-62.3M | $-4.0M |
| Gross Margin | — | 36.8% |
| Operating Margin | -847.6% | -77.8% |
| Net Margin | -766.0% | -75.1% |
| Revenue YoY | -79.3% | -12.5% |
| Net Profit YoY | -765.1% | -236.7% |
| EPS (diluted) | $-1.13 | $-0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $5.3M | ||
| Q3 25 | — | $7.2M | ||
| Q2 25 | — | $7.3M | ||
| Q1 25 | $8.1M | $7.3M | ||
| Q4 24 | $15.3M | $6.1M | ||
| Q3 24 | $26.0M | $5.6M | ||
| Q2 24 | $27.4M | $4.7M | ||
| Q1 24 | $39.3M | $6.2M |
| Q4 25 | — | $-4.0M | ||
| Q3 25 | — | $-2.1M | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | $-62.3M | $-659.9K | ||
| Q4 24 | $-47.1M | $-1.2M | ||
| Q3 24 | $-25.9M | $-930.4K | ||
| Q2 24 | $-27.2M | $-1.5M | ||
| Q1 24 | $-7.2M | $-1.1M |
| Q4 25 | — | 36.8% | ||
| Q3 25 | — | 30.4% | ||
| Q2 25 | — | 33.8% | ||
| Q1 25 | — | 44.3% | ||
| Q4 24 | — | 45.0% | ||
| Q3 24 | — | 44.1% | ||
| Q2 24 | — | 44.0% | ||
| Q1 24 | — | 41.6% |
| Q4 25 | — | -77.8% | ||
| Q3 25 | — | -29.2% | ||
| Q2 25 | — | -19.4% | ||
| Q1 25 | -847.6% | -8.2% | ||
| Q4 24 | -348.2% | -18.7% | ||
| Q3 24 | -129.1% | -15.5% | ||
| Q2 24 | -127.8% | -31.2% | ||
| Q1 24 | -40.3% | -17.0% |
| Q4 25 | — | -75.1% | ||
| Q3 25 | — | -29.7% | ||
| Q2 25 | — | -20.1% | ||
| Q1 25 | -766.0% | -9.1% | ||
| Q4 24 | -308.4% | -19.5% | ||
| Q3 24 | -99.4% | -16.5% | ||
| Q2 24 | -99.3% | -32.5% | ||
| Q1 24 | -18.3% | -17.9% |
| Q4 25 | — | $-0.14 | ||
| Q3 25 | — | $-0.07 | ||
| Q2 25 | — | $-0.06 | ||
| Q1 25 | $-1.13 | $-0.03 | ||
| Q4 24 | $-0.87 | $-0.05 | ||
| Q3 24 | $-0.48 | $-0.04 | ||
| Q2 24 | $-0.51 | $-0.06 | ||
| Q1 24 | $-0.14 | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $543.3M | $12.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $416.9M | $21.6M |
| Total Assets | $648.1M | $37.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $12.4M | ||
| Q3 25 | — | $15.3M | ||
| Q2 25 | — | $1.6M | ||
| Q1 25 | $543.3M | $4.1M | ||
| Q4 24 | $587.4M | $5.4M | ||
| Q3 24 | $574.3M | $1.3M | ||
| Q2 24 | $516.7M | $841.9K | ||
| Q1 24 | $573.9M | $1.5M |
| Q4 25 | — | $21.6M | ||
| Q3 25 | — | $25.5M | ||
| Q2 25 | — | $9.1M | ||
| Q1 25 | $416.9M | $9.6M | ||
| Q4 24 | $454.8M | $10.2M | ||
| Q3 24 | $483.0M | $11.3M | ||
| Q2 24 | $487.2M | $12.2M | ||
| Q1 24 | $496.6M | $13.7M |
| Q4 25 | — | $37.0M | ||
| Q3 25 | — | $41.5M | ||
| Q2 25 | — | $28.4M | ||
| Q1 25 | $648.1M | $29.7M | ||
| Q4 24 | $711.3M | $31.1M | ||
| Q3 24 | $764.9M | $27.5M | ||
| Q2 24 | $734.3M | $27.2M | ||
| Q1 24 | $779.7M | $28.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-63.1M | $-2.6M |
| Free Cash FlowOCF − Capex | $-63.9M | $-2.6M |
| FCF MarginFCF / Revenue | -786.4% | -49.3% |
| Capex IntensityCapex / Revenue | 9.6% | 0.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-122.5M | $-10.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-2.6M | ||
| Q3 25 | — | $-3.6M | ||
| Q2 25 | — | $-2.6M | ||
| Q1 25 | $-63.1M | $-1.2M | ||
| Q4 24 | $-46.0M | $4.2M | ||
| Q3 24 | $30.7M | $-207.3K | ||
| Q2 24 | $-36.2M | $-157.9K | ||
| Q1 24 | $-31.9M | $248.2K |
| Q4 25 | — | $-2.6M | ||
| Q3 25 | — | $-3.6M | ||
| Q2 25 | — | $-2.7M | ||
| Q1 25 | $-63.9M | $-1.3M | ||
| Q4 24 | $-47.5M | $4.0M | ||
| Q3 24 | $28.4M | $-489.6K | ||
| Q2 24 | $-39.5M | $-609.6K | ||
| Q1 24 | $-38.3M | $143.3K |
| Q4 25 | — | -49.3% | ||
| Q3 25 | — | -50.6% | ||
| Q2 25 | — | -37.7% | ||
| Q1 25 | -786.4% | -17.9% | ||
| Q4 24 | -311.3% | 66.6% | ||
| Q3 24 | 109.2% | -8.7% | ||
| Q2 24 | -144.1% | -12.9% | ||
| Q1 24 | -97.7% | 2.3% |
| Q4 25 | — | 0.9% | ||
| Q3 25 | — | 1.0% | ||
| Q2 25 | — | 2.0% | ||
| Q1 25 | 9.6% | 1.8% | ||
| Q4 24 | 9.8% | 2.1% | ||
| Q3 24 | 8.8% | 5.0% | ||
| Q2 24 | 11.7% | 9.6% | ||
| Q1 24 | 16.4% | 1.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACLX
Segment breakdown not available.
TGEN
| Installation Services | $4.5M | 84% |
| Products Segment | $460.5K | 9% |
| Other | $394.7K | 7% |
